ROS1 Alterations as a Potential Driver of Gliomas in Infant, Pediatric, and Adult Patients
David M Meredith1, Linda D Cooley2, Adrian Dubuc1
1Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Summary
This study reveals ROS1 fusion-positive gliomas in infants, children, and adults, highlighting distinct molecular profiles and poorer outcomes in adults. ROS1 likely drives these brain tumors, suggesting targeted therapy potential.
Area of Science:
- Neuro-oncology
- Molecular Pathology
- Genomics
Background:
- Gliomas with ROS1 alterations are rare, predominantly seen in infants.
- Understanding the full spectrum of ROS1 fusion-positive gliomas across age groups is crucial.
Conclusions:
- This is the largest study characterizing ROS1 fusion-positive gliomas across all age groups.
- ROS1 is likely a driver in infant and pediatric gliomas and a driver or codriver in adult gliomas.
- Comprehensive clinical testing may identify patients for targeted therapy.
